PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Phase 2

Completed

• Conditions: Adenocarcinoma
• Interventions: Drug: ABT-806; Drug: Ramucirumab; Drug: Trastuzumab; Drug: Nivolumab; Drug: Bemarituzumab; Drug: Standard cytotherapy

• Registration Number: NCT02213289
• Lead Sponsor: University of Chicago

Brief Summary

The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-08-01
• Study First Submitted QC: 2014-08-08
• Study First Posted: 2014-08-11
• Study Start: 2015-01-20
• Primary Completion: 2020-02-01
• Study Completion: 2020-08-20
• Results First Submitted: 2021-01-29
• Status Verified: 2021-03
• Results First Submitted QC: 2021-03-15
• Last Update Submitted: 2021-03-15
• Results First Posted: 2021-04-08
• Last Update Posted: 2021-04-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Histologically confirmed metastatic gastric or esophagogastric junction (type I,II,III Siewert) adenocarcinoma

2. Newly-diagnosed chemo-naïve or recurrent after curative-intent surgery

   • >6 months after completion of adjuvant therapy (including chemotherapy and/or radiotherapy)
   • No prior treatment with any targeted agent
   • Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening.

3. Measurable metastatic disease by RECIST criteria,

   • Must be amenable to ultrasound or CT-guided biopsy of one metastatic lesion
   • Peritoneal disease as the sole site of occult metastasis or presenting as malignant ascites is acceptable if a cell block of tumor cells can be obtained showing >20% viable tumor cells.

4. ECOG PS 0,1

5. Age > 18 years

6. Patients must have normal organ and marrow function as defined below:

   • granulocytes >1,2500/mcL
   • platelets >100,000/mcL
   • total bilirubin < 1.5 x ULN, <1.8 x ULN with liver metastases
   • AST(SGOT)/ALT(SGPT) <2.5 X ULN without liver metastases; <5 X ULN with liver metastases
   • creatinine within normal institutional limits (<1.5) OR
   • creatinine clearance >50 mL/min/1.73m2, (for creatinine level above normal)
   • INR: < 1.5 (patients on warfarin need to be converted to LMWH during study participation to be eligible)

7. Consent to baseline metastatic and progressive disease biopsy (of metastatic/progressing lesion) for enabling biomarker assessment and treatment assignment (at each time point - baseline, PD1, PD2, PD3) as well as for correlative studies.

   • Consent to baseline and serial blood draws for plasma/serum/whole blood banking for correlative studies

8. Ability to understand and the willingness to sign a written informed consent document and consent to the serial nature of the proposed PANGEA treatment with first, second and third line therapy as tolerated.

9. Ability to comply with requirements of the protocol, as assessed by the investigator by the patient signing the consent form.

10. If history of exposure to anthracyclines during perioperative treatment, the following cumulative doses of anthracyclines must be less than:

    Epirubicin < 720 mg/m2 Doxorubicin or liposomal doxorubicin < 360 mg/m2 Mitoxantrone > 120 mg/m2 and idarubicin > 90 mg/m2 If more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.

11. Cardiac Ejection Fraction >50% (for HER2+ patients) as assessed by echocardiogram, MUGA scan, or cardiac MRI

12. Willingness to use effective and reliable methods of contraception (For appropriate methods of contraception considered acceptable see Appendix B).

Both men and women and members of all races and ethnic groups are eligible for this trial.

Read More

Exclusion Criteria

1. No CVA within 6 months, no recent MI within 6 months
2. No currently active second malignancy
3. No uncontrolled intercurrent illness or infection
4. No peripheral edema > grade 2 at baseline.
5. No peripheral neuropathy > grade 2 at baseline.
6. No diarrhea > grade 2 at baseline.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)	Standard cytotherapy	For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows: Immuno-oncology included PD-L1 IHC combined positivity score \>10, high microsatellite instability, tumor mutation burden \>15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab.
ITT-PTS: Personalized Treatment Strategy (HER2 amplified)	Standard cytotherapy	HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
ITT-PTS: Personalized Treatment Strategy (EFGR amplified)	ABT-806	EGFR amplified. These patients received ABT-806.
ITT-PTS: Personalized Treatment Strategy (EFGR amplified)	Standard cytotherapy	EGFR amplified. These patients received ABT-806.
ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)	Standard cytotherapy	FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)	Standard cytotherapy	MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
ITT-PTS: Personalized Treatment Strategy (EGFR expressing)	ABT-806	EGFR expressing. These patients received standard cytotherapy plus ABT 806.
ITT-PTS: Personalized Treatment Strategy (EGFR expressing)	Standard cytotherapy	EGFR expressing. These patients received standard cytotherapy plus ABT 806.
ITT-PTS: Personalized Treatment Strategy (All negative)	Ramucirumab	All negative. These patients received standard cytotherapy plus Ramucirumab.
ITT-PTS: Personalized Treatment Strategy (All negative)	Standard cytotherapy	All negative. These patients received standard cytotherapy plus Ramucirumab.
Non-ITT: Standard Therapy	Standard cytotherapy	Patients without monoclonal antibodies available received standard cytotherapy.
ITT-PTS: Personalized Treatment Strategy (HER2 amplified)	Trastuzumab	HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)	Nivolumab	For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows: Immuno-oncology included PD-L1 IHC combined positivity score \>10, high microsatellite instability, tumor mutation burden \>15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab.
ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)	Ramucirumab	MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)	Bemarituzumab	FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.

Primary Outcome Measures

Name	Time	Method
Overall Survival	Up to 60 months	Time from enrollment to death from any cause.

Secondary Outcome Measures

Name	Time	Method
Completion of Biopsy and Successful, Molecularly-based Treatment Assignment	Up to 1 month	Completion of biopsies with successful assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).
Adverse Event From Serial Biopsy for Second-line Treatment	Up to 60 Months	Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)
Completion of Serial Biopsy for Second Line Therapy and Successful, Molecularly-based Treatment Assignment	Up to 60 months	Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).
Number of Biopsies Leading to an Adverse Event	1 Month	Number of biopsies leading to an adverse event of the total undergoing baseline biopsies of a primary and metastatic disease site (liver, lung, lymph node, peritoneum/carcinomatosis).
Adverse Event From Serial Biopsy for Third-line Treatment	Up to 60 months	Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)
Completion of Serial Biopsy for Third Line Therapy and Successful, Molecularly-based Treatment Assignment	Up to 60 months	Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).

Trial Locations

Locations (1)

University of Chicago; 🇺🇸 Chicago, Illinois, United States